Arzneimittelforschung 2011; 61(4): 260-265
DOI: 10.1055/s-0031-1296197
Antibiotics · Antimycotics · Antiparasitics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

Efficacy of vitamin C vaginal tablets in the treatment of bacterial vaginosis: a randomised, double blind, placebo controlled clinical trial

Eiko E Petersen
1   Former Head of Department for Infection Disease in Gynaecology and Obstetrics, Women's Hospital, University of Freiburg, Germany
Margherita Genet
2   Scientific Department, Polichem SA, Lugano, Switzerland
Maurizio Caserini
2   Scientific Department, Polichem SA, Lugano, Switzerland
Renata Palmieri
2   Scientific Department, Polichem SA, Lugano, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
27 November 2011 (online)


A randomised, double blind, parallel groups, placebo controlled clinical trial was conducted to assess the efficacy and safety profile of 250 mg ascorbic acid (Vit. C, Vagi C®) in women with bacterial vaginosis (BV). Overall, 277 out-patients with at least three of the following signs (white discharge that smoothly coats the vaginal walls, pH of vaginal fluid >4.5, a fishy odour of vaginal discharge before or after addition of 10% KOH and presence of clue cells on microscopic examination) were randomised to apply a tablet deeply into the vagina once daily for 6 days. The primary efficacy endpoint was the cure rate, defined as the recovery of all inclusion criteria. In the intent-to-treat (ITT) population, cure was achieved by 55.3 % of patients with Vit. C (n = 141) and by 25.7 % of patients with placebo (n = 136). The between-group difference was 29.6 % (p < 0.001). In the per-protocol (PP) population, cure rate was 66.4 % with Vit. C (n = 116) and 27.1 % with placebo (n = 118), respectively. Between-group difference was 39.3 % (p < 0.001). In a subset of patients with centralised evaluation of the vaginal swab, cure in ITT was achieved by 86.3 % of patients with Vit. C (n = 51) and by 7.6 % of patients with placebo (n = 53), the between-group difference was 78.7 % (p < 0.0001). Cure rate in PP was 86.0 % with Vit. C (n = 50) and 6.1 % with placebo (n = 49), between-group difference was 79.9 % (p < 0.0001). Both Vit. C and placebo were well tolerated and no differences in safety profile were evident between groups.

The results support an effective and safe use of silicon-coated Vit. C vaginal tablets in the management of BV.

  • References

  • 1 Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001–2004 National Health and Nutrition Examination Survey data. Obstet Gynecol. 2007; 109 (1) 114-20
  • 2 Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006; 4 (55) (RR-11) 1-94 Erratum in: MMWR Recomm Rep. 2006;15;55(36):997
  • 3 Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006; 1 193 (11) 1478-86
  • 4 Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983; 74: 14-22
  • 5 Owen MK, Clenney TL. Management of vaginitis. Am Fam Physician. 2004; 70: 2125-32
  • 6 Swedberg JA. Bacterial vaginosis: etiology, association with preterm labor, diagnosis and management. Compr Ther. 1989; 15 (8) 47-53
  • 7 McGregor JA, French JI, Parker R, Draper D, Patterson E, lones W et al. Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation. AmJ Obstet Gynecol. 1995; 173: 157-67
  • 8 Clindamycin; Metronidazole. In: Martindale. The complete drug reference. London: Pharmaceutical Press; 2007. p. 225-227 753–757.
  • 9 Austin MN, Beigi RH, Meyn LA, Hillier SL. Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J Clin Microbiol. 2005; 43 (9) 4492-7
  • 10 Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect. 2004; 80: 8-11
  • 11 Boeke AJ, Dekker JH, van Eijk JT, Kostense PJ, Bezemer PD. Effect of lactic acid suppositories compared with oral metronidazole and placebo in bacterial vaginosis: a randomised clinical trial. Genitourin Med. 1993; 69 (5) 388-92
  • 12 UNEP publications [Internet]. OECD SIDS data set on L-as-corbic acid (vitamin C). 2010; [Cited 2010 July 20]. Available from:
  • 13 Polatti F, Rampino M, Magnani P, Mascarucci P. Vaginal pH-lowering effect of locally applied vitamin C in subjects with high vaginal pH. Gynecol Endocrinol. 2006; 22 (4) 230-4
  • 14 Petersen EE, Magnani P. Efficacy and safety of vitamin C vaginal tablets in the treatment of non-specific vaginitis: a randomized, double-blind, placebo-controlled study. Eur J Obstet GynecolReprod Biol. 2004; 117 (1) 70-5
  • 15 Abbaspoor Z. Comparison effect of vitamin C vaginal tablet with metronidazole vaginal gel treatment and relapse of bacterial vaginosis. Proceedings of the 19th European Congress of Clinical Microbiology and Infectious Diseases. 2009; May 16–19 Helsinki, Finland
  • 16 Holley RL, Richter HE, Verner RE, Pair L, Schwebke JR. A randomized, double-blind clinical trial of vaginal acidification versus placebo for the treatment of symptomatic bacterial vaginosis. Sex Transm Dis. 2004; 31 (4) 236-8
  • 17 Prodigy Guidance: Bacterial vaginosis. Revision May 2006. Available from: